Tabula Rasa HealthCare (Nasdaq:TRHC) - Aktienkurs, Nachrichten und Analyse

TRHC Aktienübersicht

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States.

TRHC grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	1/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	2/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 13.23%

Risikoanalyse

Negatives Eigenkapital

Die Aktionäre wurden im vergangenen Jahr verwässert

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Tabula Rasa HealthCare, Inc. Wettbewerber

SOPHiA GENETICS

NasdaqGS:SOPH

US$270.1m

TruBridge

NasdaqGS:TBRG

US$172.1m

Sharecare

NasdaqGS:SHCR

US$526.7m

American Well

NYSE:AMWL

US$146.9m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Tabula Rasa HealthCare
Historische Aktienkurse
Aktueller Aktienkurs	US$10.50
52-Wochen-Hoch	US$10.50
52-Wochen-Tief	US$3.15
Beta	1.58
11 Monat Veränderung	1.16%
3 Monate Veränderung	34.10%
1 Jahr Veränderung	203.47%
33 Jahre Veränderung	-70.13%
5 Jahre Veränderung	-85.61%
Veränderung seit IPO	-29.44%

Aktuelle Nachrichten und Updates

Recent updates

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 84% Above Its Share Price

Jul 26

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Jun 28

We Discuss Why Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) CEO Compensation May Be Closely Reviewed

Jun 05

Tabula Rasa HealthCare, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Tabula Rasa HealthCare, Inc.'s (NASDAQ:TRHC) Intrinsic Value Is Potentially 60% Above Its Share Price

Apr 02

Tabula Rasa HealthCare (NASDAQ:TRHC) Is Carrying A Fair Bit Of Debt

Mar 12

Update: Tabula Rasa HealthCare (NASDAQ:TRHC) Stock Gained 51% In The Last Three Years

Feb 19

Aktionärsrenditen

	TRHC	US Healthcare Services	US Markt
7D	0.9%	-2.0%	0.6%
1Y	203.5%	0.3%	32.1%

Rendite im Vergleich zur Industrie: TRHC übertraf die Branche US Healthcare Services, die im vergangenen Jahr eine Rendite von -3.2 erzielte.

Rendite vs. Markt: TRHC übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is TRHC's price volatile compared to industry and market?
TRHC volatility
TRHC Average Weekly Movement	8.6%
Healthcare Services Industry Average Movement	9.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: TRHCDer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: TRHCDie wöchentliche Volatilität (9%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2009	1,027	Brian Adams	www.tabularasahealthcare.com

Tabula Rasa HealthCare, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Tabula Rasa HealthCare im Vergleich zum Marktanteil des Unternehmens?
TRHC grundlegende Statistiken
Marktanteil	US$284.03m
Gewinn(TTM)	-US$61.07m
Umsatz(TTM)	US$338.12m

0.8x

Kurs-Umsatz-Verhältnis

-4.7x

Kurs-Gewinn-Verhältnis

Ist TRHC zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TRHC Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$338.12m
Kosten der Einnahmen	US$258.28m
Bruttogewinn	US$79.84m
Sonstige Ausgaben	US$140.91m
Umsatz	-US$61.07m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.26
Bruttomarge	23.61%
Nettogewinnspanne	-18.06%
Schulden/Eigenkapital-Verhältnis	-418.7%

Wie hat sich TRHC auf lange Sicht entwickelt?

Historische Performance und Vergleiche

TRHC Aktienübersicht

Belohnungen

Risikoanalyse

Tabula Rasa HealthCare, Inc. Wettbewerber

NasdaqGS:SOPH

US$270.1m

NasdaqGS:TBRG

US$172.1m

NasdaqGS:SHCR

US$526.7m

NYSE:AMWL

US$146.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

New minor risk - Share price stability

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

CEO, President & Director exercised options and sold US$117k worth of stock

Price target increased by 14% to US$8.38

Consensus EPS estimates upgraded to US$1.33 loss

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 11% to US$7.30

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to US$1.49 loss

Price target increased to US$6.33

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Price target decreased to US$5.92

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Consensus forecasts updated

Price target increased to US$6.42

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Price target increased to US$6.75

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

Price target decreased to US$5.71

Price target decreased to US$6.33

Continuing To Avoid Tabula Rasa HealthCare Inc.

Consensus revenue estimates fall by 25%

Does Tabula Rasa HealthCare (NASDAQ:TRHC) Have A Healthy Balance Sheet?

First quarter 2022 earnings: EPS misses analyst expectations

Price target decreased to US$9.92

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought US$58k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 22% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Is Tabula Rasa HealthCare (NASDAQ:TRHC) Using Too Much Debt?

Calculating The Fair Value Of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Co-President recently sold US$95k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Why Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) Could Be Worth Watching

Insufficient new directors

Erträge & Einnahmen